ImmuPharma plc (FRA:25I)

Germany flag Germany · Delayed Price · Currency is EUR
0.0800
+0.0225 (39.13%)
At close: Nov 27, 2025
515.38%
Market Cap36.60M
Revenue (ttm)n/a
Net Income (ttm)-4.59M
Shares Outn/a
EPS (ttm)-0.01
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,125
Average Volume106
Open0.0645
Previous Close0.0575
Day's Range0.0645 - 0.0800
52-Week Range0.0005 - 0.2180
Betan/a
RSI39.38
Earnings DateMay 18, 2026

About ImmuPharma

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which is in Phase III clinical trial that targets autoimmune diseases for systemic lupus erythematosus; P140, which is in Phase II clinical trial for the treatment of chronic inflammatory demyelinating polyneuropathy, a rare acquired aut... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1999
Employees 6
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 25I
Full Company Profile

Financial Performance

Financial numbers in GBP Financial Statements

News

There is no news available yet.